Published in Nat Rev Cancer on October 01, 2003
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
Making sense of cancer genomic data. Genes Dev (2011) 3.01
The yeast coexpression network has a small-world, scale-free architecture and can be explained by a simple model. EMBO Rep (2004) 2.75
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A (2005) 1.64
Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci U S A (2004) 1.35
pHUSH: a single vector system for conditional gene expression. BMC Biotechnol (2007) 1.27
Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights (2010) 1.11
The full-ORF clone resource of the German cDNA Consortium. BMC Genomics (2007) 1.11
Optimizing RNA interference for application in mammalian cells. Biochem J (2004) 1.09
Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci U S A (2010) 0.93
Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis. Oncogene (2011) 0.90
Bcl-2 is a critical mediator of intestinal transformation. Nat Commun (2016) 0.87
Generation of RNAi libraries for high-throughput screens. J Biomed Biotechnol (2006) 0.86
Pooled RNAi Screens - Technical and Biological Aspects. Curr Genomics (2010) 0.84
Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proc Natl Acad Sci U S A (2014) 0.82
Designer siRNAs to overcome the challenges from the RNAi pathway. J RNAi Gene Silencing (2005) 0.76
TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens. BMC Bioinformatics (2014) 0.76
Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes. Genes Cancer (2016) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem (2003) 2.14
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81
Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81
The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol (2010) 1.77
A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev (2002) 1.65
E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell (2002) 1.59
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56
Re-evaluating cell-cycle regulation by E2Fs. Cell (2006) 1.46
TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem (2001) 1.46
E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene (2004) 1.44
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell (2005) 1.34
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One (2009) 1.29
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27
A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol (2002) 1.25
PR72, a novel regulator of Wnt signaling required for Naked cuticle function. Genes Dev (2005) 1.21
Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle (2006) 1.17
TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nat Cell Biol (2010) 1.13
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res (2006) 1.09
Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem (2008) 1.09
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. Proc Natl Acad Sci U S A (2006) 1.07
Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med (2011) 1.05
The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Mol Cancer Res (2010) 1.04
Cancer: cues for migration. Nature (2003) 0.97
A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS Genet (2007) 0.95
UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res (2009) 0.95
Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res (2010) 0.94
An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol (2013) 0.93
Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat (2012) 0.93
High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem (2003) 0.91
Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation. Mol Cell Biol (2003) 0.91
TGF-β: an emerging player in drug resistance. Cell Cycle (2013) 0.90
A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol (2013) 0.90
A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. J Biol Chem (2006) 0.89
Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res (2008) 0.87
Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res (2010) 0.87
Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res Treat (2011) 0.86
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol (2008) 0.86
Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis (2009) 0.85
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer (2014) 0.84
Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle (2014) 0.84
Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet (2013) 0.83
Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res (2009) 0.80
Functional annotation of deubiquitinating enzymes using RNA interference. Methods Enzymol (2005) 0.80
Wip-ing out cancer. Nat Genet (2004) 0.79
Cancer: Entangled pathways. Nature (2008) 0.79
An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression. Oncogene (2004) 0.77
Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med (2008) 0.75
Functional subtyping of breast cancer. Cancer Discov (2011) 0.75